Wednesday, February 10, 2010, 11:52AM AEST - The Australian Stockmarket closes in 4 hours and 13 minutes.
To create a watchlist or portfolio of shares, Register

Affymax, Inc. (AFFY)

8:00AM AEST: 20.26 USD  Up 0.18 (0.90%)  
 MORE ON AFFY 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Affymax, Inc. (NGM:AFFY) Delayed quote dataEdit
Last Trade:20.26 USD
Trade Time: 8:00AM AEST
Change:Up 0.18 (0.90%)
Prev Close:20.08
Open:19.99
Bid:19.35 x 100
Ask:21.11 x 100
1y Target Est:31.83
Day's Range:19.86 - 20.67
52wk Range:11.79 - 25.64
Volume:54,904
Avg Vol (3m):155,015
Market Cap:387.41M
P/E (ttm):N/A
EPS (ttm):-5.05
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y 
 Add AFFY to Portfolio   Download Data

 HEADLINES 
10 Biotech Stocks on Clinical Trials Watch
at TheStreet.com (Thu, Feb 4)
Affymax to Present at the 12th Annual BIO CEO & Investor Conference
Business Wire (Tue, Feb 2)
Amgen Up Despite Q4 Sales, Profit Miss
at Barrons.com (Tue, Jan 26)
Affymax Completes Treatment and Last Patient Follow-up in Phase 3 Program for Investigational Drug, Hematide, to Treat Anemia in Chronic Renal Failure
Business Wire (Tue, Jan 26)
AFFYMAX INC Files SEC form 8-K, Change in Directors or Principal Officers
EDGAR Online (Tue, Jan 12)
Amgen's Anemia Drug Risks; Vivus Aids Sleep Apnea: BioBuzz
at TheStreet.com (Thu, Jan 7)
FDA to Review Amgen Drugs: BioBuzz
at TheStreet.com (Thu, Jan 7)
Affymax to Present at the 28th Annual JP Morgan Healthcare Conference
Business Wire (Wed, Jan 6)
AFFYMAX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation
EDGAR Online (Fri, Dec 11)
Affymax to Present at Piper Jaffray 21st Annual Healthcare Conference
Business Wire (Wed, Dec 2)
Research Firm Lays Out Surprise Bio Events for 2010: BioBuzz
at TheStreet.com (Tue, Dec 1)
More Headlines for AFFY...

 ANALYST 
EPS Est (next year) (Dec-09) :-4.72
EPS Est (in 2 years) (Dec-10) :-1.10
Avg Rec (current)*:1.5
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices